BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, April 17, 2026
Home
»
Newsletters
» BioWorld
BioWorld
May 17, 2010
View Archived Issues
Pharma Outlicensing: From Opportunism to R&D Funding
A common theme heard around the hallways of the BIO 2010 International Convention earlier this month was that the big pharma firms in attendance were doing more selling than buying.
Read More
Money Raised Year to Date
Read More
Savient for Sale, Ardea Bid Adds Dose: Gout on Move
Read More
German Plan: Blood in Water for Overseas Reimbursement?
Read More
Money Raised By Biotech in 2010
Read More
Week in Review
Read More
Word on the Street
Read More
FDA Approvals in April
Read More
Phase I Clinical Trials Update: April 2010
Read More
Phase II Clinical Trials Update: April 2010
Read More
Pivotal/Phase III Clinical Trials Update: April 2010
Read More
Non-U.S. Clinical Trials And Regulatory Actions: April 2010
Read More
FDA Submissions, Approvals And Other Actions: April 2010
Read More
Stock Gainers and Losers For The Week
Read More
BioWorld Stock Report For Public Biotechnology Companies
Read More
